LONDON— AstraZeneca PLC has applied for an emergency European license of the Covid-19 vaccine developed by Oxford University, a step towards more pictures being spread across the region as diseases and hospitals arise.
The EU drug regulator said Tuesday it could approve the vaccine as early as January 29 after completing a review of clinical trial data. The European Pharmaceutical Agency’s main scientific committee will meet that day after further analysis of test results and safety and manufacturing data. It is likely that the European Commission would recommend any proposal to discontinue the vaccine within a day or two.
That timeline could eventually add 400 million doses to Europe’s vaccine arsenal as the region struggles with a deadly winter surge of the virus, exacerbated by the spread of a past variant. first discovered in the UK The EU has released 300 million doses of the Oxford-AstraZeneca vaccine, with an option for an additional 100 million.
Last week, Europe cleared a vaccine developed by Moderna Inc. for emergency use, giving the area a second look at Covid-19. The blockchain is struggling to release its doses, after being vaccinated by Pfizer Inc. and German partner BioNTech SE in December.
Circulation over 27 member states is infested with logistic bottles and challenges with ultracold storage requirements that make circulation wide. Some governments in early Europe expected the Oxford-AstraZeneca vaccine to be on the market first, leaving them unprepared for the logistics of the freezer of the Pfizer-BioNTech design, resulting in a slow, non- horizontal.